Brezivaptan (developmental code names ANC-501, THY-1773, TS-121) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder. As of November 2022, it is in phase II clinical trials for this indication.
See also ABT-436 Balovaptan List of investigational antidepressants Nelivaptan SRX-246
References
External links